Results 251 to 260 of about 205,561 (359)
Vacancy defect‐induced electron homing breaks phosphodiester bonds for RNA depletion‐driven cancer therapy
BMEMat, EarlyView.Illustration of 5% S‐vacancy Bi2S3 mediated phosphodiester bonds cleavage in RNA of hepatocellular carcinoma cells, which suppressing ERI3 expression, inhibiting cell proliferation and promoting apoptosis. Abstract
Genome‐wide hypertranscription is a hallmark of malignant progression.Chuncheng Yang, Zehao Shen, Guangming Xiang, Zhe Liu, Huaxin Liu, Jiabei Li, Ao Wang, Yelin Wu, Peiran Zhao, Xingwu Jiang, Jinghan Wang, Xiaoqing Jiang, Wenbo Bu +12 morewiley +1 more sourceA novel matrine derivative, WM130, inhibits activation and movement of human hepatic stellate LX-2 cells by targeting cofilin 1
, 2022 Yang Xu, Jingui Duan, Weidan Ji, Chao Liu, Xiang Li, Qiuye Wu, Chunfang Gao, Changqing Su +7 moreopenalex +2 more sourcesTransendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial
ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.Abstract Aims
The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of
the EXCELLENT Trial Investigators +17 morewiley +1 more sourceThe induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib
, 2016 Annkristin Heine, Judith Schilling, Barbara T. Grünwald, Achim Krüger, Heidrun Gevensleben, Stefanie Andrea Erika Held, Natalio Garbi, Christian Kurts, Peter Brossart, Percy A. Knolle, Linda Diehl, Bastian Höchst +11 moreopenalex +2 more sourcesInterpretation of in vitro concentration‐response data for risk assessment and regulatory decision‐making: Report from the 2022 IWGT quantitative analysis expert working group meeting
Environmental and Molecular Mutagenesis, EarlyView.Abstract
Quantitative risk assessments of chemicals are routinely performed using in vivo data from rodents; however, there is growing recognition that non‐animal approaches can be human‐relevant alternatives. There is an urgent need to build confidence in non‐animal alternatives given the international support to reduce the use of animals in toxicity ...Marc A. Beal, Guangchao Chen, Kerry L. Dearfield, Min Gi, Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Alexandra S. Long, David P. Lovell, Barbara L. Parsons, Stefan Pfuhler, John Wills, Andreas Zeller, George Johnson, Paul A. White +14 morewiley +1 more sourceEpithelial membrane protein 1 drives hepatic stellate cell activation via the TLN1/FAK cascade in MASLD donor liver transplantation. [PDF]
Mol BiomedLi T, Liu R, Cao H, Deng S, Wang G, Wang X, Zhao P, Li X, Zhu J, Shao S, Chen H, Liu L, Zhang C, Yin C, Song Z. +14 moreeuropepmc +1 more sourceOne‐Stone‐Two‐Birds Carrier‐Free Nano‐Cocktail Enables Synergistic Eradication of Cancer Cells/Stem Cells in Breast Cancer Treatment
Exploration, EarlyView.ABSTRACT
Cancer stem cells (CSCs) are widely recognized as the culprits of chemoresistance, tumor metastasis, and relapse. Moreover, most chemotherapeutic drugs not only fail to eliminate CSCs effectively, but also induce the acquisition of stemness characteristics in non‐stem cancer cells. Herein, we propose a cancer cells/CSCs double‐killing modality Tongyao Zhao, Yao Chen, Haimeng Yuan, Shuqian Yang, Hongyuan Zhang, Yuequan Wang, Shenwu Zhang, Qin Chen, Jin Sun, Zhonggui He, Cong Luo +10 morewiley +1 more source